Cellectis
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Cellectis and buy or sell other stocks, ETFs, and their options commission-free!About CLLS
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J.
CEOAndré Choulika
CEOAndré Choulika
Employees222
Employees222
HeadquartersParis, Ile-de-France
HeadquartersParis, Ile-de-France
Founded2000
Founded2000
Employees222
Employees222
CLLS Key Statistics
Market cap265.32M
Market cap265.32M
Price-Earnings ratio-10.34
Price-Earnings ratio-10.34
Dividend yield—
Dividend yield—
Average volume65.51K
Average volume65.51K
High today$3.66
High today$3.66
Low today$3.59
Low today$3.59
Open price$3.66
Open price$3.66
Volume975.00
Volume975.00
52 Week high$5.48
52 Week high$5.48
52 Week low$1.10
52 Week low$1.10
CLLS News
TipRanks 6d
Cellectis S.A. Sets March 19 Release Date for Q4 and Full-Year 2025 ResultsAn announcement from Cellectis SA ( (CLLS) ) is now available. Cellectis S.A., a clinical-stage biotechnology company specializing in gene-edited, off-the-shel...
Analyst ratings
75%
of 8 ratingsBuy
75%
Hold
25%
Sell
0%
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.